Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun;51(6):778-85.
doi: 10.1038/bmt.2016.18. Epub 2016 Feb 22.

Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey

D Niederwieser  1   2 , H Baldomero  1 , J Szer  3 , M Gratwohl  4 , M Aljurf  5 , Y Atsuta  6 , L F Bouzas  7 , D Confer  8 , H Greinix  9 , M Horowitz  10 , M Iida  11 , J Lipton  12 , M Mohty  13 , N Novitzky  14 , J Nunez  15 , J Passweg  1 , M C Pasquini  10 , Y Kodera  16 , J Apperley  17 , A Seber  18 , A Gratwohl  1
Affiliations

Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey

D Niederwieser et al. Bone Marrow Transplant. 2016 Jun.

Abstract

Data on 68 146 hematopoietic stem cell transplants (HSCTs) (53% autologous and 47% allogeneic) gathered by 1566 teams from 77 countries and reported through their regional transplant organizations were analyzed by main indication, donor type and stem cell source for the year 2012. With transplant rates ranging from 0.1 to 1001 per 10 million inhabitants, more HSCTs were registered from unrelated 16 433 donors than related 15 493 donors. Grafts were collected from peripheral blood (66%), bone marrow (24%; mainly non-malignant disorders) and cord blood (10%). Compared with 2006, an increase of 46% total (57% allogeneic and 38% autologous) was observed. Growth was due to an increase in reporting teams (18%) and median transplant activity/team (from 38 to 48 HSCTs/team). An increase of 167% was noted in mismatched/haploidentical family HSCT. A Strengths, Weaknesses, Opportunities, Threats (SWOT) analysis revealed the global perspective of WBMT to be its major strength and identified potential to be the key professional body for patients and authorities. The limited data collection remains its major weakness and threat. In conclusion, global HSCT grows over the years without plateauing (allogeneic>autologous) and at different rates in the four World Health Organization regions. Major increases were observed in allogeneic, haploidentical HSCT and, to a lesser extent, in cord blood transplantation.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: There are no conflicts of interests.

Figures

Figure 1
Figure 1. Global HSCT activity in 2012
a: Absolute number of HSCT (allogeneic and autologous combined) in participating countries by WHO regional offices area in 2012. Regions are colored by WHO regional offices area code (see text). Shades of colors reflect absolute transplant numbers. b: Transplant rates of allogeneic and autologous HSCT combined / 10 million population in participating countries by WHO regional offices area in 2012. Regions are colored by WHO regional offices area code (see text). c: Use of allogeneic compared to autologous HSCT in participating countries by WHO regional offices area in 2012. Regions are colored by WHO regional offices area code (see text). Darker colors indicate preferred use of allogeneic HSCT. d: Use of family donor HSCT in participating countries by WHO regional office areas in 2012. Regions are colored by WHO regional office area code (see text). Darker colors indicate preferred use of family donors compared to unrelated donor HSCT. e: Use of HSCT for malignant indications compared to non-malignancies in participating countries by WHO regional office area in 2012. Regions are colored by WHO regional office area code (see text). Darker colors indicate preferred use of HSCT for malignant indications.
Figure 2
Figure 2. Proportions of indications for HSCT
a: Global indications for 31,926 patients with an allogeneic HSCT in 2012 b: Global indications for 36,220 patients with an autologous HSCT in 2012
Figure 3
Figure 3. Global trends 2006 – 2012
a. Increase in absolute numbers of global HSCT from 2006 to 2012. Colors depict allogeneic (blue), autologous (red) and total HSCT (green). b. Increase in absolute numbers of allogeneic HSCT from 2006 to 2012 by WHO region (for definitions see text). Colors depict AMR/PAH (blue), SEAR/WPR (red), EUR (green) and EMR/AFR (purple). c. Increase in absolute numbers of autologous HSCT from 2006 to 2012 by WHO region. Colors depict AMR/PAH (blue), SEAR/WPR (red), EUR (green) and EMR/AFR (purple). Abbreviations: AMR/PAH, Region of the Americas; SEAR/WPR, South-East Asia Region and Western Pacific; EUR European Region; EMR/AFR Eastern Mediterranean Region and African Region.
Figure 4
Figure 4. Trends in use of allogeneic HSCT
a. Global trends in use of family vs unrelated donors (left panel) and global trend in use of cord blood products or haploidentical donors (right panel). b. Use of haploidentical HSCT (left panel) or unrelated cord blood products (right panel) by WHO region. Abbreviations: AMR/PAH, Region of the Americas; SEAR/WPR, South-East Asia Region and Western Pacific; EUR European Region; EMR/AFR Eastern Mediterranean Region and African Region.
See this image and copyright information in PMC

References

    1. World Health Organization. WHO guiding principles on human cell, tissue and organ transplantation. Transplantation. 2010;90(3):229–33. - PubMed
    1. White SL, Hirth R, Mahíllo B, Domínguez-Gil B, Delmonico FL, Noel L, et al. The global diffusion of organ transplantation: trends, drivers and policy implications. Bull World Health Organ. 2014;92:826–35. - PMC - PubMed
    1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, et al. Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303:1617–24. - PMC - PubMed
    1. Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas LF, Horowitz M, et al. Worldwide Network of Blood and Marrow Transplantation (WBMT).Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica. 2013;98(8):1282–90. - PMC - PubMed
    1. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Yoshiko, Baldomero Helen, Foeken Lydia, et al. For the Worldwide Network of Blood and Marrow Transplantation WBMT. One million haemopoietic stem- cell transplants: a retrospective observational study. Lancet Haematology. 2015;2:e91–100. - PubMed

MeSH terms